Advaxis Inc

Advaxis — Investor Presentation (November 2009)

32 slides from Advaxis's investor presentation, Nov 3, 2009

  1. Slide 1: Investor Presentation Fall 2009

    Investor Presentation Fall 2009 SY

  2. Slide 2: Safe Harbor Disclosure

    e Harbor Disclosure THIS PRESENTATION CONTAINS “FORWARD-LOOKING STATEMENTS” WITHIN THE MEANING OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. SUCH FORWARD-LOOKING STATEMENTS INVOLVE KNOWN AND UNKNOWN RISKS, UNCERTAINTIES AND OTHER FACTORS WHICH MAY CAUSE THE ACTUAL RESULTS, PERFORMANCE OR

  3. Slide 3: Advaxis, Inc. (OTCBB: ADXS) overview

    AdVaxis, Inc. (OTCBB: ADXS) lis The only commercially-developed bacterial cancer vaccine company using live and attenuated Listeria monocytogenes (Lm), as a carrier of bioengineered tumor antigens. o Headquartered in the Technology Center of NI © Technology discovered and developed out of the microb

  4. Slide 4: The human immune system

    UMAN IMMUNE SYSTE The body's immune system is a collection of biological processes that protect it against disease by identifying and killing pathogens and tumor cells. The immune system protects organisms from infection with a tiered defense system of increasing specificity. When a pathogen enters

  5. Slide 5: Immunology: Killer and Helper T cells

    OLOGY: “Killer” and Helper Antigen presenting cells (APC) activate T cells to become: oCytotoxic (“Killer” CD8+) T cells directly attack other cells carrying certain foreign or abnormal molecules on their surfaces OR o“Helper” (CD4+) T cells coordinate immune responses by communicating with other ce

  6. Slide 6: T cells kill cancer cells

    T CELLS KILL CANCER CELLS Cytotoxic T-cells (T,) release cytotoxins that form pores in the target cell's plasma membrane causing them to leak and die. anzymesenter into the cancer cell and activate a series of enzymes that lead to an apoptosis — programmed cell death.

  7. Slide 7: Exception to the rule: tumors and immune tolerance

    Dendritic cell causing a T cell to be activated against a specific target CEPTION TO THE RULE Cancer cells often develop in healthy people. Our immune system normally clears these cells before they become a tumor. However, when tumors develop, the immune system diminishes and does not generate an im

  8. Slide 8: Our delivery system

    OUR DELIVERY SYSTEM Bioengineered Induced Immunotherapy Factoid: Most people already have a profound immune response to Lm because it appears in our food routinely in leafy vegetables, dairy products and meat. Listeria in action

  9. Slide 9: Listeria monocytogenes

    Listeria monocytogenes Awild Lm bacterium is selected to be the delivery vector and “attenuated” to lessen its virulence by 10,000 times. Wild Type Listeria

  10. Slide 10: Step 2: The genetic sequencing

    STEP;2THE GENETIC SEQUENCING Antigen/Adjuvant Fusing A genetic sequence is engineered becoming the template for a tumor specific antigen (tumor target) fused to a modified Lm protein — listeriolysin-O (LLO) — that allows the bacterium to synthesize and secrete the active antigen/adjuvant within the

  11. Slide 11: Step 3: The bioengineering

    STEPS ?THE BIOENGINEERING Plasmids Created and Inserted Engineering the Plasmid A plasmid, containing Advaxis eee. bioengineered genetic code, is Then, about a dozen Advaxis bioengineered plasmids are inserted into the living Lm delivery vector system.

  12. Slide 12: Step 4: The factory

    STEP'4: THE FACTORY. Advaxis’ Trojan Horse A revolutionary immunotherapeutic technology that makes the active drug and secretes it where it is used within the cells that need it. Attenuated Genetically Engi The result: = ‘ © activates the cellular immune system o. stimulates a powerful immune respon

  13. Slide 13: What happens next

    at Happens Next Antigen presenting cells (APC) ingest an Advaxis bioengineered Lm bacterium, which becomes encapsulated. A iat However, some Lm bacteria will perforate the phagosome membrane and escape int In turn, pathogens are digested in the newly- combined phagolysosomes that break down most bac

  14. Slide 14: Immune system directs a comprehensive response against the tumor

    Immune system takes the antigen and directs a comprehensive immune response developed for Lm against the tumor Affects: Y Simultaneous and robust innate and adaptive immunological response Targets cancer and infectious diseases Breaks antigen tolerance consistently Delivers immediate therapeutic eff

  15. Slide 15: Groundbreaking intra-tumoral effects

    Groundbreaking intra-tumoral effects Activated Tumor Killing T-Cells Vaccine (IN THE TUMOR) Lm-£7 (- LLO) 9.4% 11.8% ‘ADXS11-001 (+ LLO) 36.8% 1.7% 400% increase in cytotoxic T-Cell activation inside the tumor 80% reduction in regulatory T-cells inside the tu

  16. Slide 16: Pre-clinical/clinical trials: animals and humans

    PRE-CLINICAL/CLINICAL TRIALS Animals and Humans FACTOID: ¥75% tumor clearance in normal animals through use of different Lm vaccines across many cancer models Up to 50% tumor clearance in transgenic animals that are immunotolerant to cancer across different experiments ¥ Long-term immunity in respon

  17. Slide 17: ADXS11-001 versus other vaccines

    XS11-001 Versus Other Vaccines Vaccine Tumor-free mice National Cooperative Drug () Discovery Group (NCI) independent study to test tumor ADXS11-001 50-100 vaccines in side-by-side test: SN Lm-E7 0 ADXS11-001 most efficacious in Vac-Sig-E7 0-25 inal Vac-E7 0 BoNK i Out performed: = Vaccinia E7 in SB

  18. Slide 18: First therapy to the clinic against cervical cancer (HPV16-E7)

    Sign: first therapy to the clinic against cervical cancer (HPV16-E7), The pr soo! 1umed etiologic oncogene of 57% of cervical cancers and 33% ead and neck cancers Plan: cThree (3) groups of five (5) patients each, treated with 1.0 billion; 3.3, billion; 10.0 billion bacteria Two (2) same-dose admini

  19. Slide 19: Phase 1 patient tumor burden and response

    ISE GROUP. PATIENT TUMOR BURDEN % CHANGE RESPONSE 1.0%10° 01-001 142.500 Progressive RS Progressive Patent End stage, flled first-line therapy Stalite Dose: instead of 3 Response: All dosage groups Stable Stable 33x10" | Outof 13 evaluable patients: Sebe © Tumor progression: 5 © Tumor stabilization:

  20. Slide 20: Phase 1 trial study: survival

    01 Phase | Trial Study: Sur GseGrour PATENT stuovonv——owreorocarn STUBLDAYAT. LASTOATE. ASAE ovo a6amRos =a G6 ne m Ton sural Median soviol‘SAe ‘ 8 ‘av (a ADXS11-001 Phase | Clinical Trial 53 347. 23% / 1,000+ ovo —~—«aotcoe =~ MANO @ oor 3487 : ren) &0 02.006 04-006, 15:MAR.O7 158-07 Lost toFU. aoa

  21. Slide 21: Clinical pipeline

    LINICAL PIPELINE ME construct —inoication —pHase PATENT stage spONSOR START (@) ‘ADXS11-001 Cervical cancer 1 15 Late Advaxis Completed aoxsazoon *Mealdislesi® yg cary—acvans «Jan 2020 atl Cancer ns ADKSIL-001 Cerviclcancer = M68 ana 20 (GOG/NCI) ADKSILO0 —_Cervialeancer HO _—iate india Tan 2010 ADK

  22. Slide 22: Other vaccines in development

    ER VACCINES IN DEVELOPMENT ANTIGEN INDICATION HMW-MAA Anti-angiogenesis, melanoma ps3 Many Cancer Types Wri Lymphoma(s), Leukemia(s), Ovarian, Others Telomerase Many Cancer Types Survivin Ovarian, Sarcomas cA9 Hypoxic Tumors IL-a3ra. Glioma Advaxis can bioengineer dual antigen systems that can attac

  23. Slide 23: Patent portfolio

    Patent Portfolio 23 patents issued Composition of matter, methods and uses covering: — LiveLm * Four (4) different Listeria species = LLO-antigen fusion proteins * Delivered by Lm or stand alone + Two (2) different families of adjuvant fusions * Safe, modified LLO 48 patents pending and/or ongoing a

  24. Slide 24: Financial Information

    FINANCIAL INFORMATION — 34 Quarter 2009 (unaudited) SY

  25. Slide 25: Pro-forma revenue chart

    Pro-forma Revenue Chart DOSES MARKET SHARE | —_REVENUES. INDICATION MARKET | INCIDENCE -3 PP- (40%) $2,000 PER DOSE - (in mitions) _(in millions) _- PROJECTED- || _{S,inmilions) CN us 0.480 71380 0540 1080 Top7 1.000 3.000 4.200 2.400 Cenvcal us 0.025 0750 0.200 00 Top? 0.080 2.400 0.960 1.920 Prost

  26. Slide 26: Ped ar

    Ped ar 12 0 “say 8 Renu 5 soe 630) CCE tsa Twat Opectng Eerste 5 ees 28085 one see lesen cron rer) cy (ess waeresose denne inbity 2om20 * anise see eon eee cee ase) T89 aaa rey eres sx 20% tncone Danae tert 7 ma waar ro 7 Wiss income fossa Carmen Sik sms wzorw, cox, wane $a, tosicoepershe, se me Sea

  27. Slide 27: Advaxis, Inc. trading statistics

    ADVAXIS, INC Ticker symbol Exchange Share price 52.week Hi-Lo 52.week change Shares outstanding Market capitalization Enterprise value Float Average volume Short position Insider position -astittional position ope apy oTces (October 22, 2009) $0.14 ($, a/o October 22, 2008) 0.21 -0.01 (4) 43.0 (in m

  28. Slide 28: Thomas A. Moore

    Thomas A. Moore Chairman of the Board of Directors, CEO and President Mr. Moore brings more than 25 years of experience in healthcare and executive management. He has served on the Advaxis (OTCBB: ADXS) Board of Directors since September 2006 and has been the Company's CEO since December 2006. He ha

  29. Slide 29: Dr. John Rothman, PhD

    Dr. John Rothman, PhD Executive VP, Science & Operations Dr. Rothman brings more than 30 years of clinical knowledge and expertise in the disciplines of infectious disease, gastroenterology, neurology, oncology and virology. He has been with Advaxis since March 2008. ‘Along his career, Dr. Rothman h

  30. Slide 30: Clinical team: Dr. Christine C. Chansky

    CLINICAL yr. Christine C. Chansky, MD, JD, FCLM. Executive Director, Product Development Dr. Chansky comes to the company with over 15 years of professional expertise in health care compliance and FDA regulations with comprehensive experience in drug development, pharmaceutical promotional regulatio

  31. Slide 31: Fund raising events

    ouse Fund Raising Events OCT 2007: $9.4 million common stock/warrant financing — corporate refinancing NOV 2008: $1.0 million non-dilutive financing — NOL sale to NIEDA JAN 2009: $1.0 million private loan ~ Chairman/CEO Thomas A. Moore JUN 2009: $1.0 million private debt financing — high net-worth i

  32. Slide 32: Thank You!

    Thank You! Advaxis, Inc. (OTCBB:ADXS) NJ Technology Center 675 US Route One, South North Brunswick, NJ 08902 732.545.1590 (Office) | 732.545.1084 (FAX) ir@advaxis.com www.advaxis.com EEE «Linke. Gui

Advaxis — Investor Presentation (November 2009) on 6ix